Navigation Links
OctreoPharm Sciences Receives Orphan Drug Designation for SOMscan® for the Diagnosis of Neuroendocrine Tumours
Date:10/12/2011

BERLIN, October 12, 2011 /PRNewswire/ --

OctreoPharm Sciences GmbH, a Berlin based specialist for radiopharmaceuticals, announced today that the European Medicines Agency has granted Orphan Drug status to OctreoPharm Sciences product SOMscan® for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.

The Orphan Drug status entitles OctreoPharm Sciences to ten year market exclusivity in Europe following marketing approval for SOMscan®. The designation also provides for special benefits, including possible exemptions in certain regulatory fees during development.

"We are proud to have received this Orphan Drug Designation for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours" said Dr. Hakim Bouterfa, Managing Director and Head of R&D. Udo Blaseg, Managing Director and Head of Operations added: "This designation is an important step for a new and heavily improved diagnostic and staging tool for a seriously debilitating and potentially lethal disease."

About SOMscan™

SOMscan is a new Gallium-68-labeled radioactive contrast agent for positron emission tomography with the potential to detect neuroendocrine tumors currently in Phase I. It binds to four out of five specific tumor receptor subtypes on the surface of neuroendocrine tumors. This may allow detection of neuroendocrine tumors which previously escaped discovery in imaging. The diagnosis of neuroendocrine tumors with SOMscan has the potential to be faster, more accurate, more reliable and more specific.

About OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company intends to acquire licenses for other product candidates as well. OctreoPharm Sciences is in particular on the lookout for collaborations with pharmaceutical companies which focus on products for personalized medicine and new therapeutic agents.

Contact:
Udo Blaseg
OctreoPharm Sciences GmbH
Robert-Rössle-Straße 10
13125 Berlin
Phone:  +49(0)30-9489-3360
eMail:  info@octreopharm.com



'/>"/>
SOURCE OctreoPharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
2. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
3. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
4. SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner
5. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
6. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
7. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
8. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
9. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
10. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
11. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):